Diagnosis and treatment of peripheral arterial disease compared with other atherosclerotic vascular diseases in a University Primary Care Clinic

Journal of Investigative Medicine

Volumn 54, Issue 5, 2006, Pages 255-261

  Ismail, Hassan M ^a   Jackson, Kyoo ^a   Smith, Daniel ^a  

^a East Tennessee State University   (United States)

Author keywords

Atherosclerotic vascular disease; Cerebrovascular disease (CVD); Coronary artery disease (CAD); Peripheral arterial disease (PAD); The PAD Awareness Risk and Treatment: New Resources for Survival (PARTNERS); The San Diego Artery study

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIAGNOSTIC APPROACH ROUTE; DRUG CONTRAINDICATION; DRUG INDICATION; FEMALE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREVALENCE; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VASCULAR DISEASE;

EID: 33845895988     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/6650.2006.05049     Document Type: Article

References (45)

1. th ed. New York: McGraw-Hill; 2004. p. 2361-79.
2. Creager MA, Dzau VJ. Vascular diseases of the extremities. In: Harrison's principles of internal medicine. 16th ed. New York: McGraw-Hill; 2005. p. 1486-9.
3. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110:1245-50.
4. Okrainec K, Banerjee DK, Eisenberg MJ, Coronary artery disease in the developing world. Am Heart J 2004;148:7-15.
5. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1380-1.
6. Aronow WS, Ahn C. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women ≥ 62 years of age. Am J Cardiol 1994;74:64-5.
7. Kannel WB, Mcgee DL. Update on some epidemiologic features of intermittent claudication: The Framingham Study. J Am Geriatr Soc 1985;33:13-8.
8. Sukhija R, Aronow WS, Yalamanchili K, et al. Prevalence of coronary artery disease, lower extremity peripheral arterial disease, and cerebrovascular disease in 110 men with an abdominal aortic aneurysm. Am J Cardiol 2004;94:1358-9.
9. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004;110:738-43.
10. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-6.
11. Hertzer NR. The natural history of peripheral vascular disease: implications for its management. Circulation 1991;83 Suppl 2:112-9.
12. Vogt MT, Cauley JA, Newman AB, et al. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 1993;270:465-9.
13. Weitz JI, Byrne J, Clagett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996;94:3026-9.
14. TransAtlantic Inter-society Consensus (TASC) Working Group. J Vasc Surg 2000;31(1 Suppl, Pt 2):S1-296.
15. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-39.
16. Newman AB, Shemanski L, Manolio TA, et al. The Cardiovascular Health Study Collaborative Research Group. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999;19:538-45.
17. Papamichael CM, Lekakis JP, Stamatelopoulos KS, et al. Ankle-brachial index as a predictor of the extent of coronary atherosclerosis and cardiovascular events in patients with coronary artery disease. Am J Cardiol 2000;86:615-8.
18. Sikkink CJ, Van Asten WN, Van't Hof MA, et al. Decreased ankle/brachial indices in relation to morbidity and mortality in patients with peripheral arterial disease. Vasc Med 1997;2: 169-73.
19. Hiatt WR. Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy. J Intern Med 2002;251:193-206.
20. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med 2004;164: 2106-10.
21. Aronow WS. Antiplatelet therapy in peripheral arterial disease. Curr Drug Targets Cardiovasc Haematol Disord 2004;4:265-7.
22. Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol 1991;18:1587-93.
23. Fields WS, Lemak NA, Frankowski RF, et al. Controlled trial of aspirin in cerebral ischemia. Circulation 1980;62(6 Pt 2): V90-6.
24. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone; a recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomized, double blind, placebo-controlled trial. Lancet 2004;364:331-7.
25. Garg R, Elam EB, Crouse JR, et al. Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. Am Heart J 2000;140:792-803.
26. Pettinger MB, Waclawiw MA, Davis KB, et al. Compliance to multiple interventions in a high-risk population. Ann Epidemiol 1999;9:408-18.
27. National Center for Health Statistics. International classification of diseases, ninth revision, clinical modification (ICD-9-CM). Hyattsville (MD): National Center for Health Statistics; 2004.
28. Woodwell DA, Cherry DK. National Ambulatory Medical Care Survey: 2002 summary, Division of Health Care Statistics, US Department of Health and Human Services. Advance Data, Vital and Health Statistics 2004;346:1-44.
29. Rojas-Fernandez CH, Kephart GC, Sketris IS, Kass K. Under use of acetylsalicylic acid in individuals with myocardial infarction, ischemic heart disease or stroke: data from the 1995 population-based Nova Scotia Health survey. Can J Cardiol 1999;15:291-6.
30. National Center for Health Statistics, Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/ nchs/ (accessed Dec 29, 2005).
31. Huang JV, Casebeer AW, Plomondon ME, et al. Prescription-filling rates for key medications in Veterans Affairs patients after coronary artery bypass grafting. Am J Health Syst Pharm 2004;61:1248-52.
32. Geber J, Parra D, Beckey NP, Korman L. Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting. Pharmacotherapy 2002;22:738-47.
33. Hamann GF, Weimar C, Glahn J, et al. Adherence to secondary stroke prevention strategies: results from the German Stroke Data Bank. Cerebrovasc Dis 2003;15:282-8.
34. Lahad A, Anshelevitz V, Sonnenblick M, Dwolatzky T. The use of accepted preventive medicine practice among elderly patients in community clinics in the Jerusalem area. Isr Med Assoc J 2003;5:352-5.
35. Komiya T, Kudo M, Urabe T, Mizuno Y. Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Assessment by platelet aggregation testing. Stroke 1994;25:2337-42.
36. Hill JW, Roglieri JL, Warburton SW. Aspirin treatment after myocardial infarction: are health maintenance organization members, women, and the elderly undertreated? Am J Manag Care 1998;4:51-8.
37. Tufano A, Cerborne AM, Di Minno G. The use of antithrombotic drugs in older people. Minerva Med 2002;93:13-26.
38. Burney KD, Krishnan K, Ruffin MT, et al. Adherence to single daily dose of aspirin in a chemoprevention trial. An evaluation of self-reporting and microelectronic monitoring. Arch Fam Med 1996;5:297-300.
39. Allen LaPointe NM, Kramer JM, DeLong ER, et al. Patient-reported frequency of taking aspirin in a population with coronary artery disease. Am J Cardiol 2002;89:1042-6.
40. Short D, Frischer M, Bashford J, Ashcroft D. Why are eligible patients not prescribed aspirin in primary care? A qualitative study indicating measures for improvement. BMC Fam Pract 2003;4:9.
41. Fornarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMPS). Am J Cardiol 2001;87:819-22.
42. Frances CD, Alperin P, Adler JS, Grady D. Does a fixed physician reminder system improve the care of patients with coronary artery disease? A randomized controlled trial. West J Med 2001;175:165-6.
43. Filippi A, Sabatini A, Badioli L, et al. Effects of an automated electronic reminder in changing the antiplatelet drug-prescribing behavior among Italian general practitioners in diabetic patients: an intervention trial. Diabetes Care 2003;26: 1497-500.
44. Black DM. The development of combination drugs for atherosclerosis. Curr Atheroscler Rep 2003;5:29-32.
45. Talbert RL, Spinier SA, Nappi JM, Bottorff MB. Combination antiplatelet therapy: implications for pharmacists. J Am Pharm Assoc (Wash) 2002;42:880-3.